Edwards Lifesciences Corp (EW)vsHyperfine Inc (HYPR)
EW
Edwards Lifesciences Corp
$82.67
+1.20%
HEALTHCARE · Cap: $48.01B
HYPR
Hyperfine Inc
$1.15
-4.96%
HEALTHCARE · Cap: $120.49M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 44636% more annual revenue ($6.07B vs $13.56M). EW leads profitability with a 17.7% profit margin vs -2.6%. EW earns a higher WallStSmart Score of 55/100 (C).
EW
Buy55
out of 100
Grade: C
HYPR
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-544.4%
Fair Value
$12.31
Current Price
$82.67
$70.36 premium
Intrinsic value data unavailable for HYPR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 23.7%
Revenue surging 128.0% year-over-year
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 76.6%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -79.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.
Bull Case : HYPR
The strongest argument for HYPR centers on Revenue Growth, Price/Book. Revenue growth of 128.0% demonstrates continued momentum.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.
Bear Case : HYPR
The primary concerns for HYPR are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
EW profiles as a mature stock while HYPR is a hypergrowth play — different risk/reward profiles.
HYPR carries more volatility with a beta of 1.11 — expect wider price swings.
HYPR is growing revenue faster at 128.0% — sustainability is the question.
EW generates stronger free cash flow (354M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 25/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Hyperfine Inc
HEALTHCARE · MEDICAL DEVICES · USA
Hyperfine Inc. is a pioneer in medical technology, focusing on transforming access to MRI with innovative point-of-care imaging solutions. As the developer of the first FDA-cleared portable MRI system, the company significantly enhances patient care by delivering high-quality imaging directly at the bedside, which streamlines clinical decision-making. By emphasizing cost efficiency and patient convenience, Hyperfine is strategically positioned to capitalize on the escalating demand for advanced diagnostic imaging solutions in a rapidly changing healthcare environment. Its groundbreaking technology is poised to make a substantial impact on healthcare delivery across various medical settings, representing a promising opportunity for institutional investors.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?